NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03800134,A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT03800134,AEGEAN,ACTIVE_NOT_RECRUITING,"This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemotherapy administered prior to surgery compared with placebo and chemotherapy administered prior to surgery in terms of pathological complete response.",NO,Non-Small Cell Lung Cancer,DRUG: Durvalumab|OTHER: Placebo|DRUG: Carboplatin|DRUG: Cisplatin|DRUG: Pemetrexed|DRUG: Paclitaxel|DRUG: Gemcitabine|PROCEDURE: Surgery,"Pathological Complete Response (pCR) in modified intent-to-treat (mITT) population, Defined as the lack of any viable tumour cells after complete evaluation in the resected lung cancer specimen and all sampled regional lymph nodes., Up to approximately 15 weeks after randomization|Event-Free Survival (EFS) in modified intent to treat (mITT) population, An event is defined as documented RECIST 1.1 local or distant recurrence of lung cancer; death due to any cause; disease progression that precludes surgery or discovered upon attempting surgery that prevents completion of surgery., Up to 5.5 years after first patient randomized.","Disease-free survival (DFS) in modified resected population, From date of randomization to approximately 5.5 years after date of resection|Major Pathological Response (mPR) in modified intent to treat (mITT) population, Up to approximately 15 weeks after randomization|Overall Survival (OS) in modified intent to treat (mITT) population, From date of randomization to 5.5 years after randomization|Event-free survival (EFS) in PD-L1-TC ≥1% patients in modified intent to treat (mITT) population, From date of randomization to 5.5 years after randomization|pCR in PD-L1-TC ≥1% patients in modified intent to treat (mITT) population, Up to approximately 15 weeks after randomization|Disease-Free Survival (DFS) in PD-L1-TC ≥1% patients in modified resected population, From date of randomization to 5.5 years after date of resection|Major Pathological Response (mPR) in PD-L1-TC ≥1% patients in modified intent to treat (mITT) population, Up to approximately 15 weeks after randomization|Overall Survival (OS) in PD-L1-TC ≥1% patients in modified intent to treat (mITT) population, From date of randomization to 5.5 years after randomization.|To assess disease-related symptoms and HRQoL (EORTC QLQ-C30) in patients treated with durvalumab + chemotherapy prior to surgery followed by durvalumab post-surgery compared with placebo + chemotherapy prior to surgery followed by placebo post-surgery, To assess disease-related symptoms, functioning, and global health status/quality of life in patients., From date of screening to 6 months after last dose of IP|To assess disease-related symptoms and HRQoL (EORTC QLQ-LC13) in patients treated with durvalumab + chemotherapy prior to surgery followed by durvalumab post-surgery compared with placebo + chemotherapy prior to surgery followed by placebo post-surgery, To assess disease-related symptoms, functioning, and global health status/quality of life in patients., From date of screening to 6 months after last dose of IP|To assess the PK of durvalumab in blood, To assess concentration of durvalumab in bloodstream., From date of randomization to 2 months after resection|Presence of ADA for durvalumab, To evaluate the presence of antibodies following treatment with study medications., From date of randomization to 3 months after last dose of IP","Number of participants with adverse events as assessed by CTCAE v5.0, From date of randomization to 3 months after last dose of IP",AstraZeneca,,ALL,"ADULT, OLDER_ADULT",PHASE3,825,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",D9106C00001|2018-002997-29,2018-12-06,2022-11-10,2028-09-11,2019-01-11,,2025-03-25,"Research Site, Phoenix, Arizona, 85054, United States|Research Site, Duarte, California, 91010, United States|Research Site, Orange, California, 92868, United States|Research Site, Aurora, Colorado, 80012, United States|Research Site, Boca Raton, Florida, 33486, United States|Research Site, Jacksonville, Florida, 32256, United States|Research Site, Chicago, Illinois, 60612, United States|Research Site, Wichita, Kansas, 67214, United States|Research Site, Ashland, Kentucky, 41101, United States|Research Site, Lexington, Kentucky, 40513, United States|Research Site, Silver Spring, Maryland, 20910, United States|Research Site, Towson, Maryland, 21204, United States|Research Site, Duluth, Minnesota, 55805, United States|Research Site, Minneapolis, Minnesota, 55404, United States|Research Site, Morristown, New Jersey, 07962, United States|Research Site, New York, New York, 10028, United States|Research Site, New York, New York, 10065, United States|Research Site, Shirley, New York, 11967, United States|Research Site, Durham, North Carolina, 27710, United States|Research Site, Bend, Oregon, 97701, United States|Research Site, Medford, Oregon, 97504, United States|Research Site, Pittsburgh, Pennsylvania, 15212, United States|Research Site, Charleston, South Carolina, 29414, United States|Research Site, Charleston, South Carolina, 29424, United States|Research Site, Austin, Texas, 78745, United States|Research Site, Fort Worth, Texas, 76104, United States|Research Site, Houston, Texas, 77030, United States|Research Site, Houston, Texas, 77090, United States|Research Site, Fairfax, Virginia, 22031, United States|Research Site, Kirkland, Washington, 98034, United States|Research Site, Seattle, Washington, 98109, United States|Research Site, Buenos Aires, C1118AAT, Argentina|Research Site, Caba, C1012AAR, Argentina|Research Site, Caba, C1280AEB, Argentina|Research Site, La Plata, 1900, Argentina|Research Site, Pergamino, B2700CPM, Argentina|Research Site, Rosario, S2000DEJ, Argentina|Research Site, San Salvador de Jujuy, 4600, Argentina|Research Site, Viedma, R8500ACE, Argentina|Research Site, Graz, 8036, Austria|Research Site, Innsbruck, 6020, Austria|Research Site, Rankweil, 6830, Austria|Research Site, Wien, 1090, Austria|Research Site, Wien, 1210, Austria|Research Site, Gent, 9000, Belgium|Research Site, Liège, 4000, Belgium|Research Site, Mons, 7000, Belgium|Research Site, Barretos, 14784-400, Brazil|Research Site, Belo Horizonte, 30380-090, Brazil|Research Site, Campinas, 13060-904, Brazil|Research Site, Curitiba, 81520-060, Brazil|Research Site, Florianópolis, 88034-000, Brazil|Research Site, Natal, 59075-740, Brazil|Research Site, Porto Alegre, 90610-000, Brazil|Research Site, Santa Maria, 97015-450, Brazil|Research Site, Sao Paulo, 01323-903, Brazil|Research Site, São José do Rio Preto, 15090-000, Brazil|Research Site, São Paulo, 01246-000, Brazil|Research Site, Teresina, 64049-200, Brazil|Research Site, Vitoria, 29043-260, Brazil|Research Site, Plovdiv, 4004, Bulgaria|Research Site, Sofia, 1330, Bulgaria|Research Site, Sofia, 1407, Bulgaria|Research Site, Sofia, 1797, Bulgaria|Research Site, Edmonton, Alberta, T6G 1Z2, Canada|Research Site, Kitchener, Ontario, N2G 1G3, Canada|Research Site, Levis, Quebec, G6V 3Z1, Canada|Research Site, Montreal, Quebec, H1T 2M4, Canada|Research Site, Montreal, Quebec, H4J 1C5, Canada|Research Site, Saskatoon, Saskatchewan, S7N 4H4, Canada|Research Site, Quebec, G1V 4G5, Canada|Research Site, Santiago, 7500713, Chile|Research Site, Santiago, 7500921, Chile|Research Site, Temuco, 4810469, Chile|Research Site, Viña del Mar, 2540488, Chile|Research Site, Beijing, 100021, China|Research Site, Beijing, 100029, China|Research Site, Beijing, 100191, China|Research Site, Beijing, 101149, China|Research Site, Changsha, 410008, China|Research Site, Changsha, 410013, China|Research Site, Changzhou, 213000, China|Research Site, Chengdu, 610041, China|Research Site, Guangzhou, 510095, China|Research Site, Guangzhou, 510515, China|Research Site, Guiyang, 550002, China|Research Site, Hangzhou, 310003, China|Research Site, Hangzhou, 310022, China|Research Site, Hangzhou, 310030, China|Research Site, Hangzhou, 310052, China|Research Site, Hefei, 230001, China|Research Site, Kunming, 650118, China|Research Site, Linhai, 317000, China|Research Site, Nanchang, 330006, China|Research Site, Ningbo, 315000, China|Research Site, Shanghai, 200052, China|Research Site, Shanghai, 200433, China|Research Site, Shenyang, 110042, China|Research Site, Shenyang, 110044, China|Research Site, Shenzhen, 518035, China|Research Site, Shenzhen, 518036, China|Research Site, Tianjin, 300060, China|Research Site, Urumqi, 830000, China|Research Site, Wuhan, 430060, China|Research Site, Wuhan, 430079, China|Research Site, Xiamen, 361004, China|Research Site, Xintai, 54031, China|Research Site, Yangzhou, 225001, China|Research Site, Zhengzhou, 450008, China|Research Site, San José, 1000, Costa Rica|Research Site, San José, 10108, Costa Rica|Research Site, Avignon Cedex, 84902, France|Research Site, Lyon Cedex 08, 69373, France|Research Site, Nice, 06100, France|Research Site, Toulon Cedex 9, 83800, France|Research Site, Vantoux, 57070, France|Research Site, Bielefeld, 33611, Germany|Research Site, Frankfurt am Main, 60431, Germany|Research Site, Immenstadt, 87509, Germany|Research Site, Köln, 51109, Germany|Research Site, Budapest, 1121, Hungary|Research Site, Gyöngyös - Mátraháza, 3200, Hungary|Research Site, Győr, 9024, Hungary|Research Site, Székesfehérvár, 8000, Hungary|Research Site, Törökbálint, 2045, Hungary|Research Site, Ahmedabad, 380060, India|Research Site, Gurgaon, 122001, India|Research Site, Gurgaon, 122002, India|Research Site, Kolkata, 700160, India|Research Site, Manipal, 576104, India|Research Site, Mumbai, 400012, India|Research Site, Mumbai, 400053, India|Research Site, Mysuru, 570017, India|Research Site, Namakkal, 637001, India|Research Site, Nashik, 422002, India|Research Site, New Delhi, 110076, India|Research Site, New Delhi, 110085, India|Research Site, Thane, 401107, India|Research Site, Vishakhapatnam, 530017, India|Research Site, Ancona, 60126, Italy|Research Site, Bari, 70124, Italy|Research Site, Bergamo, 24127, Italy|Research Site, Firenze, 50134, Italy|Research Site, Milano, 20132, Italy|Research Site, Monza, 20900, Italy|Research Site, Padova, 35128, Italy|Research Site, Roma, 00100, Italy|Research Site, Verona, 37126, Italy|Research Site, Habikino-shi, 583-8588, Japan|Research Site, Himeji-shi, 670-8520, Japan|Research Site, Hiroshima-shi, 730-8518, Japan|Research Site, Hiroshima-shi, 734-8551, Japan|Research Site, Iwakuni-shi, 740-8510, Japan|Research Site, Kitaadachi-gun, 362-0806, Japan|Research Site, Kitakyushu-shi, 807-8555, Japan|Research Site, Kurashiki shi, 701 0192, Japan|Research Site, Nagoya-shi, 464-8681, Japan|Research Site, Niigata-shi, 951-8566, Japan|Research Site, Okayama-shi, 700-8558, Japan|Research Site, Osakasayama-shi, 589-8511, Japan|Research Site, Toyoake-shi, 470-1192, Japan|Research Site, Wakayama-shi, 641-8510, Japan|Research Site, Busan, 48108, Korea, Republic of|Research Site, Cheongju-si, 28644, Korea, Republic of|Research Site, Seongnam-si, 13620, Korea, Republic of|Research Site, Seoul, 05505, Korea, Republic of|Research Site, Seoul, 06591, Korea, Republic of|Research Site, Suwon-si, 16499, Korea, Republic of|Research Site, Suwon, 442-723, Korea, Republic of|Research Site, Aguascalientes, 20230, Mexico|Research Site, Chihuahua, 31000, Mexico|Research Site, Guadalajara, 44680, Mexico|Research Site, Monterrey, 64000, Mexico|Research Site, Monterrey, 64710, Mexico|Research Site, México, 1400, Mexico|Research Site, México, 14050, Mexico|Research Site, Pachuca de Soto, 42090, Mexico|Research Site, Arnhem, 6815 AD, Netherlands|Research Site, Nijmegen, 6525 GA, Netherlands|Research Site, Bellavista, CALLAO 2, Peru|Research Site, Lima, LIMA 11, Peru|Research Site, Lima, LIMA 31, Peru|Research Site, Lima, Lima 32, Peru|Research Site, Lima, LIMA 34, Peru|Research Site, Davao City, 8000, Philippines|Research Site, Iloilo City, 5000, Philippines|Research Site, Makati, 1229, Philippines|Research Site, Quezon City, 1100, Philippines|Research Site, Białystok, 15-276, Poland|Research Site, Olsztyn, 10-357, Poland|Research Site, Warszawa, 02-781, Poland|Research Site, Warszawa, 04-141, Poland|Research Site, Suceava, 720237, Romania|Research Site, Kazan, 420029, Russian Federation|Research Site, Krasnoyarsk, 660133, Russian Federation|Research Site, Moscow, 105229, Russian Federation|Research Site, Moscow, 115008, Russian Federation|Research Site, Moscow, 115280, Russian Federation|Research Site, Moscow, 121205, Russian Federation|Research Site, Nizhniy Novgorod, 603081, Russian Federation|Research Site, Obninsk, 249036, Russian Federation|Research Site, Rostov-on-Don, 344037, Russian Federation|Research Site, St. Petersburg, 197022, Russian Federation|Research Site, Tomsk, 634063, Russian Federation|Research Site, Yaroslavl, 150054, Russian Federation|Research Site, Alicante, 03010, Spain|Research Site, Barcelona, 08036, Spain|Research Site, Madrid, 28040, Spain|Research Site, Málaga, 29010, Spain|Research Site, Oviedo, 33011, Spain|Research Site, Pamplona, 31008, Spain|Research Site, San Sebastian, 20014, Spain|Research Site, Santiago De Compostela (A Coruña), 15706, Spain|Research Site, Changhua, 500, Taiwan|Research Site, Taichung City, 402, Taiwan|Research Site, Taichung, 40705, Taiwan|Research Site, Tainan City, 70403, Taiwan|Research Site, Tainan City, 73657, Taiwan|Research Site, Taipei City, 110, Taiwan|Research Site, Taipei, 10002, Taiwan|Research Site, Taipei, 235, Taiwan|Research Site, Bangkok, 10300, Thailand|Research Site, Bangkok, 10330, Thailand|Research Site, Chiang Mai, 50200, Thailand|Research Site, Chiang Rai, 57000, Thailand|Research Site, Khon Kaen, 40002, Thailand|Research Site, Lampang, 52000, Thailand|Research Site, Hanoi, 100000, Vietnam|Research Site, Ho Chi Minh, 10000, Vietnam|Research Site, Ho Chi Minh, 700000, Vietnam|Research Site, Ho Chi Minh, 70000, Vietnam",
